Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Quince Therapeutics, Inc.CRTX · Entity 7403 | SVP, Legal & Administration | February 06, 2020 | February 10, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Quince Therapeutics, Inc.
Report date February 06, 2020 · Filed February 10, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $54.85 · Expires 2030-02-05 | Direct | 100,000 |
Reported balance
After 2020-02-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-02-06 · Grant · Acquired 100,000 · Balance 100,000 F1: 1/48th of the shares subject to the option shall vest and become exercisable monthly over four years. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/48th of the shares subject to the option shall vest and become exercisable monthly over four years.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 06, 2020 Filed Feb 10, 2020 23:13 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $54.85 | $0.00 |
DisclosureSEC source: 0001209191-20-008069 · doc4.xml · derivative · entry 1 Gafric Kristen · CIK 0001770840 · SVP, Legal & Administration 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-02-05 F1 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest and become exercisable monthly over four years. Read SEC document |
| August 15, 2019 Filed Aug 16, 2019 00:02 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | GrantEmployee Stock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $28.71 | $0.00 |
DisclosureSEC source: 0001209191-19-046227 · doc4.xml · derivative · entry 1 Gafric Kristen · CIK 0001770840 · SVP, Legal & Administration 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires not disclosed F1 · derivative.exercise_date: 1/48th of the total number of shares subject to this option will vest and become exercisable on each monthly anniversary of the vesting start date, beginning February 1, 2019, and for so long as the Reporting Person remains a Service Provider (as defined in the Issuer's Stock Plan). F1 · derivative.expiration_date: 1/48th of the total number of shares subject to this option will vest and become exercisable on each monthly anniversary of the vesting start date, beginning February 1, 2019, and for so long as the Reporting Person remains a Service Provider (as defined in the Issuer's Stock Plan). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.